Sep. 12 at 6:06 PM
$OCGN Interestingly, OCGN dropped 20% on the same day Nanoscope's MOGENRY BLA was accepted for filing by the FDA, Thursday, 9/9. It’s not a direct competitor to OCU400 on the broad patient population spectrum but definitely worth keeping an eye on. Negative impact they get a slight edge being the first on the market for the toughest of RP patient groups (those who have no photoreceptors remaining), positively with FDA approval the agency sends a signal that gene agnostic, or mutation-agnostic to be precise, is THE way to go and regulatively acceptable. PDUFA is expected in the first half of 2027. Not THE reason OCGN dropped obviously but may have amplified the downfall a little.
